Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
Provided By GlobeNewswire
Last update: Apr 1, 2025
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity’s Horizons in Oncology Virtual Conference.
Read more at globenewswire.com
